Core Viewpoint - Juzi Holding, the controlling shareholder of the company, has demonstrated strong confidence in the company's future by purchasing a total of 1.15 million shares for approximately HKD 62.9 million, excluding commissions and other expenses [1] Group 1 - The share purchase occurred on September 24 and 25, 2025, aimed at promoting the company's sustainable and healthy development while protecting the interests of public investors [1] - Following this acquisition, Juzi Holding now holds a total of 583 million shares, representing 54.47% of the company's total issued shares [1] - Juzi Holding may consider further increasing its stake in the company depending on market conditions and applicable regulatory requirements [1]

Core Viewpoint - Juzi Holding Co., Ltd has increased its stake in the company, demonstrating strong confidence in the company's future development and commitment to maintaining stable growth and protecting public investors' interests [1] Group 1: Share Purchase Details - On September 24 and 25, 2025, Juzi Holding purchased a total of 1.15 million shares of the company for approximately HKD 62.9 million, excluding commissions and other expenses [1] - Following this purchase, Juzi Holding holds a total of 583 million shares, representing 54.47% of the company's total issued shares [1] Group 2: Future Intentions - Juzi Holding may continue to increase its shareholding based on market conditions and applicable regulatory requirements [1]

GIANT BIOGENE HOLDING CO., LTD 巨子生物控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 獲 豁 免 有 限 公 司） （股 份 代 號：2367） 自願性公告 控股股東增持股份 本公告乃由巨子生物控股有限公司（「本公司」）自 願 作 出。兹 提 述 本 公 司 日 期 為 2025年6月9日 的 公 告，內 容 有 關 控 股 股 東 增 持 本 公 司 股 份 的 計 劃。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 本 公 司 股 東 及 有 意 投 資 者 於 買 賣 本 公 司 股 份 時 務 請 審 慎 行 事。 承董事會命 巨子生物控股有限公司 董事會主席 嚴建亞 中 國 西 安，2025年9月25日 截至本公告日期，董事會成員包括執行董事嚴建亞先生、葉娟女士、方娟女士、 張 慧 娟 女 士 及 嚴 鈺 博 女 士 以 及 獨 立 非 執 行 ...

Core Viewpoint - Juzi Holding Co., Ltd has increased its stake in Juzi Bio by purchasing a total of 2,006,600 shares for approximately HKD 105.6 million since the announcement of its buyback plan on June 9, 2025, now holding 54.45% of the company's total issued shares [1] Summary by Sections - **Share Purchase Details** - Juzi Holding has acquired 2,006,600 shares of Juzi Bio, amounting to about HKD 105.6 million excluding commissions and other expenses [1] - **Current Ownership** - Following the recent purchases, Juzi Holding now holds a total of 583,111,535 shares, representing 54.45% of the total issued shares of Juzi Bio [1] - **Future Plans** - Juzi Holding may continue to increase its shareholding in Juzi Bio depending on market conditions and applicable regulatory requirements [1]

Major Events - Chery Automobile (09973) has received a subscription rate of 308.18 times for its Hong Kong public offering [1] - Sinopec Oilfield Services (01033) has officially signed a contract for the second phase of the Ratawi oil field and inter-well pipeline project in Iraq [1] - Heng Rui Medicine (01276) has signed a licensing agreement for the Trastuzumab project with Glenmark Specialty [1] - AsiaInfo Technologies (01675) has signed a cooperation contract with Alibaba Cloud for a capability center [1] - Baidu Biotechnology-B (02315) has received approval from the Shanghai Stock Exchange's Science and Technology Innovation Board for its A-share issuance [1] Financial Data - Chow Tai Fook Enterprises (00659) reported a 3.73% year-on-year increase in net profit attributable to shareholders, reaching HKD 2.162 billion, with a final dividend of HKD 0.35 per share [1] - Nine Dragons Paper (02689) reported a 135.4% year-on-year increase in profit attributable to equity holders, amounting to approximately HKD 1.767 billion [1] - Datang New Energy Group (00559) announced an annual profit of HKD 33.614 million, marking a return to profitability [1] Buybacks and Increases - Tencent Holdings (00700) repurchased 858,000 shares at a cost of approximately HKD 550 million on September 24 [1] - Anta Sports (02020) spent HKD 188 million to repurchase 2.003 million shares on September 24 [1] - Midea Group (00300) repurchased 1.3541 million A-shares for approximately HKD 99.9934 million on September 24 [1] - Lianlian Digital (02598) plans to repurchase H-shares in the open market [1] - Giant Bio (02367) saw its controlling shareholder increase holdings by 2.0066 million shares [1] - New天绿色能源 (00956) received an increase of 1 million H-shares from its shareholder, Great Wall Life Insurance [1]

紧随本次增持后，于本公告日期，Juzi Holding合共持有公司583,111,535股股份，占公司已发行总股数 的54.45%。Juzi Holding可能会根据市场状况和适用的监管要求，不时进一步增持公司股份。 格隆汇9月24日丨巨子生物(02367.HK)公告，公司董事会接获公司控股股东Juzi Holding Co.,Ltd("Juzi Holding")通知，基于对公司未来发展的强烈信心，为促进公司持续、稳定、健康发展，维护广大公众 投资者利益，自2025年6月9日发布增持计划后，截至本公告日期，Juzi Holding于市场内合共购入200.66 万股公司股份，增持金额合计约为105.6百万港元(不包括佣金及其他开支)。 ...

巨子生物(02367)公布，董事会接获公司控股股东Juzi Holding Co.,Ltd(Juzi Holding)通知，基于对公司未 来发展的强烈信心，为促进公司持续、稳定、健康发展，维护广大公众投资者利益，自2025年6月9日发 布增持计划后，截至本公告日期，Juzi Holding于市场内合共购入200.66万股公司股份，增持金额合计约 为1.056亿港元(不包括佣金及其他开支)。紧随本次增持后，于本公告日期，JuziHolding合共持有公司约 5.83亿股股份，占公司已发行总股数的54.45%。Juzi Holding可能会根据市场状况和适用的监管要求，不 时进一步增持公司股份。 ...

智通财经APP讯，巨子生物(02367)公布，董事会接获公司控股股东Juzi Holding Co.,Ltd(Juzi Holding)通 知，基于对公司未来发展的强烈信心，为促进公司持续、稳定、健康发展，维护广大公众投资者利益， 自2025年6月9日发 布增持计划后，截至本公告日期，Juzi Holding于市场内合共购入200.66万股公司股 份，增持金额合计约为1.056亿港元(不包括佣金及其他开支)。紧随本次增持后，于本公告日期， JuziHolding合共持有公司约5.83亿股股份，占公司已发行总股数的54.45%。Juzi Holding可能会根据市场 状况和适用的监管要求，不时进一步增持公司股份。 ...

自願性公告 控股股東增持股份 本公告乃由巨子生物控股有限公司（「本公司」）自 願 作 出。兹 提 述 本 公 司 日 期 為 2025年6月9日 的 公 告，內 容 有 關 控 股 股 東 增 持 本 公 司 股 份 的 計 劃。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 GIANT BIOGENE HOLDING CO., LTD 巨子生物控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 獲 豁 免 有 限 公 司） （股 份 代 號：2367） 巨子生物控股有限公司 董事會主席 嚴建亞 中 國 西 安，2025年9月24日 截至本公告日期，董事會成員包括執行董事嚴建亞先生、葉娟女士、方娟女士、 張 慧 娟 女 士 及 嚴 鈺 博 女 士 以 及 獨 立 非 執 行 董 事 黃 進 先 生、單 文 華 先 生 及 黃 斯 穎 女 士。 本公司董事會（（「董事會」）接獲本公司控股股東 ...

Core Viewpoint - The stock of Giant Bio (02367) experienced a significant decline of 15% during trading, with a current drop of 11.8%, trading at HKD 54.2, and a transaction volume of HKD 1.716 billion. This decline is linked to allegations regarding the quality of its collagen products, which have raised concerns about potential false advertising [1]. Group 1: Company Response and Actions - Huaxi Biological has officially responded to the situation involving Dr. Hao Yu, stating that after receiving his request for assistance, it collaborated with multiple third-party testing organizations to assess the relevant products, revealing that the recombinant collagen content did not meet standards in several test results [1]. - Huaxi Biological has submitted dozens of test reports to the National Medical Products Administration, indicating a proactive approach to addressing the allegations [1]. Group 2: Allegations and Product Quality Issues - On May 24, beauty blogger Dr. Hao Yu published a report claiming that the collagen content in Giant Bio's "Collagen Stick" was only 0.0177%, significantly below the advertised standard, and that a key amino acid, glycine, was "not detected," raising suspicions of false advertising [1]. - Giant Bio quickly denied these claims, asserting that their products comply with regulations and that internal testing results exceed 0.1% [1]. - Following a series of exchanges, on June 23, Giant Bio acknowledged that its existing quality standards, testing methods, and labeling have shown limitations in certain aspects [1].